Send to

Choose Destination
Cancer Lett. 2012 Dec 28;325(2):117-24. doi: 10.1016/j.canlet.2012.06.003. Epub 2012 Jun 28.

Inhibition of HSP70: a challenging anti-cancer strategy.

Author information

Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche, University of Burgundy, Dijon, France.


HSP70 is a chaperone that accumulates in the cells after many different stresses promoting cell survival in response to the adverse conditions. In contrast to normal cells, most cancer cells abundantly express HSP70 at the basal level to resist to various insults at different stages of tumorigenesis and during anti-cancer treatment. This cancer cells addiction for HSP70 is the rational for its targeting in cancer therapy. Much effort has been dedicated in the last years for the active search of HSP70 inhibitors. Additionally, the recent clinical trials on highly promising inhibitors of another stress protein, HSP90, showed compensatory increase in HSP70 levels and raised the question of necessity to combine HSP90 inhibitors with simultaneous inhibition of HSP70. Here we analyzed the recent advancement in creation of novel HSP70 inhibitors and different strategies for their use in anti-cancer therapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center